Recursion Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview

Recursion Pharmaceuticals

03/08/2026 14:07

Recursion Pharmaceuticals Inc RXRX.OQ RXRX.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Salt Lake City Utah-based  company is expected to report a 37.9% decrease in revenue to $11.947 million from $19.22 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Recursion Pharmaceuticals Inc is for a loss of 23 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $6.00, about 100% above its last closing price of $3.00
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.28
-0.27
-0.22
Beat
18.9
Dec. 31 2026
-0.32
-0.32
-0.21
Beat
33.5
Sep. 30 2025
-0.38
-0.37
-0.36
Beat
2.7​
Jun. 30 2025
-0.33
-0.35
-0.41
Missed
-17.1
​​Mar. 31 2025
-0.44
-0.52
-0.50
Beat
4.8
Dec. 31 2024
-0.49
-0.43
-0.53
Missed
-22.8​
Sep. 30 2024
-0.35
-0.35
-0.34
Beat
2.9
Jun. 30 2024
-0.40
-0.40
-0.40
Met
-0.4
This summary was machine generated August 3 at 13:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)